Skip to main content

Advertisement

Volume 3 Supplement 1

ESICM LIVES 2015

Additional sedative drugs to light sedation with dexmedetomidine is risk for delirium

Article metrics

  • 363 Accesses

Introduction

Light sedation is preferred for critical ill patients. We often use dexmedetomidine for light sedation, but sometimes additional sedative drugs(such as midazolam and propofol) is needed. Benzodiazepine is risk for delirium, but it is unclear benzodiazepine use combined with dexmedetomidine is risk for delirium.

Methods

This prospective observational study was conducted in open ICU, urban hospital(Hiroshima, Japan) between February 2013 and March 2015. Adult patients intubated within 24 hours from ICU admission and underwent light sedation with dexmedetomidine was eligible. Exclusion criteria were: age < 18, stroke, cardiopulmonary arrest, neurosurgery, seizure, traumatic brain injury. We compared alternative sedative dug use with no additional drug. Primary outcome is delirium incidence.

Results

268 patients were eligible and 254 patients were analyzed. Median age (Q1-Q3) was 74 (66-81) years, 162 male(64%), median APACHE II score was 19 (15-23). 89 patients were administrated additional sedative drugs (midazolam 14, propofol 80). Delirium was observed more frequently compared with dexmedetomidine alone, 41 (46%) vs. 51 (31%), p = 0.02. Additional sedative drugs were associated with prolong ICU stay (5 (3-8) days vs. 3 (2-4.5) days, p < 0.001) and decreased ventilator free days (25 (21-26) days vs. 26 (26-27) days, p < 0.001).

Conclusions

Additional sedative drugs to light sedation with dexmedetomidine might be risk for delirium.

References

  1. 1.

    Pandharipande PP, Pun BT, Herr DL, et al: Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007, 298: 2644-53. 10.1001/jama.298.22.2644.

Download references

Author information

Correspondence to M Sakuraya.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Traumatic Brain Injury
  • Midazolam
  • Dexmedetomidine
  • Prospective Observational Study
  • Urban Hospital